Loading
Artivion, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 05 Mar 2025.
Artivion, Inc.: what insiders have been doing
Every trade that managers of Artivion, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. From 18 October 2025 to 18 October 2026, the disclosure feed for Artivion, Inc. logged 65 filings by 14 insiders.
Only sales appear on the open market, 39 sales in all totalling €9.8M, filed by 8 insiders. The totals exclude 2 filings filed without an amount. Biggest ticket of the year: €1.8M, sold by Mackin James P and made public on 20 August 2026 (0.18% of market cap).
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 65 filings here. Looking back to 2016, when coverage begins, insiders filed 2 purchases and 101 sales. The 10-K for the year ended 31 December 2025 shows 441.3 m USD of revenue and 9.8 m USD of net income.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
363
Thresholds
n/a
Buy Volume
€44,956
2 ops. · all time
Sell Volume
€16M
101 ops. · all time
Who traded when
BuySaleJean F. Holloway14 sales
Amy Horton9 sales
Stanton Marshall S.9 sales
John E. Davis8 sales
James P. Mackin7 sales
Andrew M. Green6 sales
+3 other insiders
Since the insiders bought
- +49.9%Entry US$24.71 · Close at T+365 US$37.04
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 17,197 of 24,148 companies
37.4
score / 100
Value32
Quality43
FCF yld0.1%
Earn yld0.9%
EV/EBITDA21.6x
ROE-0.7%
Gross mgn64%
Net mgn2.2%
Debt/EBITDA4.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$22.95
Analyst consensus
8 analysts1.25/5
US$38.00Target US$42.15(+84%)US$48.00
Income statement
RevenueUS$441.3M
Gross profitUS$284.2M64% margin
EBITDAUS$63.8M14% margin
Net incomeUS$9.8M-0.7% margin
Valuation
PER (trailing)108.5x
PER (forward)30.7x
P/Book2.5x
Beta1.25
Balance sheet & cash
Market capUS$1.1B
Total debtUS$257.6M
Free Cash FlowUS$839k
Debt / Equity92%
Profitability & ownership
ROE-0.7%
ROA2.6%
% insiders4.3%
% institutions96.3%
Last declaration on 11 September 2026
Declarations363 total
11,480 shares@ US$24.970.025% mcap13.4% of flowCommon StockSEC:0001628280-26-061602:0
11,480 shares@ US$24.97010.025% mcap13.4% of flowCommonSEC144:0001959173-26-006850
6,510 shares@ US$27.2650.016% mcap8.3% of flowCommon StockSEC:0001628280-26-060667:0
1,493 shares@ US$26.0160.0035% mcap1.8% of flowCommon StockSEC:0001628280-26-060667:1
1,493 shares@ US$26.01620.0035% mcap1.8% of flowCommonSEC144:0001959173-26-006726
7,400 shares@ US$26.85060.018% mcap7.2% of flowCommonSEC144:0001959173-26-006490
70,000 shares@ US$28.9550.18% mcap17.8% of flowCommon StockSEC:0001628280-26-058212:0
70,000 shares@ US$29.330.18% mcap100.0% of flowCommonSEC144:0001959173-26-006228
616 shares@ US$28.5490.0016% mcap0.8% of flowCommonSEC144:0001959173-26-006035
715 shares@ US$28.5490.0018% mcap1.6% of flowCommonSEC144:0001959173-26-006039
977 shares@ US$28.490.0025% mcap0.6% of flowCommon StockSEC:0001628280-26-056381:0
14,001 sharesCommon StockSEC:0001628280-26-043059:0
14,001 sharesCommon StockSEC:0001628280-26-043059:1
30,000 sharesCommon StockSEC:0001628280-26-043059:2
30,000 sharesCommon StockSEC:0001628280-26-043059:3
44,001 shares@ US$20.69850.077% mcap42.8% of flowCommonSEC144:0001959173-26-004573
6,325 shares0Common StockSEC:0001628280-26-040860:0
6,325 shares0Common StockSEC:0001628280-26-040860:1
7,850 shares0Common StockSEC:0001628280-26-036713:0
21,838 shares0Common StockSEC:0001628280-26-014894:0
40,874 shares0Common StockSEC:0001628280-26-014890:0
116,948 shares0Common StockSEC:0001628280-26-014887:0
7,475 shares0Common StockSEC:0001628280-26-014898:0
27,795 shares0Common StockSEC:0001628280-26-014896:0
28,845 shares0Common StockSEC:0001628280-26-014892:0
25 of 363 declarations
About Artivion, Inc.
Artivion, Inc. is a U.S.-listed medical technology company traded on the NYSE under the ticker AORT, not on NASDAQ. Headquartered in Kennesaw, Georgia, United States, near Atlanta, the company has built a focused franchise around aortic disease and, more broadly, cardiac and vascular surgery. Founded in 1984 and formerly known as CryoLife, Artivion has evolved through a mix of organic development and targeted acquisitions into an international niche player with more than 1,600 employees and commercial/manufacturing operations across multiple regions.
The business is organized around three complementary pillars. First, Artivion sells aortic medical devices, including aortic stent grafts, arch-related endovascular solutions, and products used in the treatment of complex aortic disease. Second, the company markets On-X mechanical heart valves, a recognized brand in valve surgery. Third, it offers surgical sealants, notably BioGlue, alongside preservation services for human tissues, which provide a more recurring and differentiated revenue stream in transplant and cardiac surgery workflows. This mix of implantable devices, consumables, and services gives Artivion a hybrid profile, combining innovation risk, clinical adoption dynamics, and a built-in installed base among surgeons and hospitals.
Read moreShow less
From a competitive standpoint, Artivion positions itself as a pure-play specialist in aortic care, a narrower but highly technical segment of the cardiovascular market. The company seeks to differentiate through clinical expertise, breadth of portfolio, and a pipeline aimed at complex open and endovascular procedures. It also emphasizes global reach, with revenue exposure across North America, Europe, the Middle East and Africa, Asia Pacific, and Latin America. That geographic spread helps reduce concentration risk, although regulatory timing and approval cycles remain crucial drivers of execution.
Recent developments are strategically important. In April 2026, Artivion announced U.S. FDA approval of Endospan’s NEXUS Aortic Arch System, a milestone that could materially expand its arch-aorta platform. In May 2026, the company said it had exercised its option to acquire Endospan, reinforcing its strategy to build a more comprehensive aortic portfolio. Operationally, full-year 2025 and early 2026 results pointed to continued revenue momentum, with gains in stent grafts, On-X, preservation services, and BioGlue. For investors, Artivion is best viewed as a specialized healthcare stock on the NYSE in the United States, driven by medical innovation, regulatory approvals, and the monetization of an increasingly integrated aortic franchise.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
